Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880450 | 0.95 | PARP1 (0.47) | CXCR4CYP2D6PARP1PARP2KCNH2 | |
| SCHEMBL4887119 | 0.92 | CXCR4 (0.51) | CXCR4KCNH2 | |
| SCHEMBL4887226 | 0.91 | CXCR4 (0.50) | CXCR4KCNH2CHRM2 | |
| SCHEMBL4889375 | 0.91 | CXCR4 (0.46) | CXCR4KCNH2 | |
| SCHEMBL4889690 | 0.91 | CXCR4 (0.48) | CXCR4CYP2D6KCNH2CHRM2DRD2 | |
| SCHEMBL4891352 | 0.90 | CXCR4 (0.45) | CXCR4CYP2D6KCNH2CHRM2DRD2 | |
| SCHEMBL4889221 | 0.90 | CXCR4 (0.49) | CXCR4KCNH2 | |
| SCHEMBL4889514 | 0.89 | CXCR4 (0.48) | CXCR4KCNH2CHRM2 | |
| SCHEMBL4881767 | 0.89 | CXCR4 (0.46) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL4882759 | 0.89 | CXCR4 (0.48) | CXCR4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | claimed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CYP2D6 4070/4885PARP1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.